|
Weight Gain
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
|
19030233 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Phospholipid measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium.
|
21829377 |
2011 |
|
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Unlike the AD setting, in the striatum from Huntington's disease (HD) transgenic mice, an increased STIM2 expression causes elevated synaptic SOCE that was suggested to underlie synaptic loss in medium spiny neurons.
|
29623030 |
2018 |
|
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Store-operated Ca<sup>2+</sup> entry (nSOC) pathway is disrupted in AD spines due to downregulation of STIM2 protein.
|
27641664 |
2017 |
|
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We propose that EB3 is involved in regulation of dendritic spines morphology, in part due to its association with STIM2, and that modulation of EB3 expression is a potential way to overcome synaptic loss during AD.
|
29247211 |
2017 |
|
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Obtained results suggest that downregulation of STIM2-dependent stability of mushroom spines and reduction in activity of synaptic CaMKII is a mechanism of hippocampal synaptic loss in AD model of amyloid synaptotoxicity and that modulators/activators of this pathway may have a potential therapeutic value for treatment of AD.
|
26275606 |
2015 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining of primary melanomas and lymph node metastases revealed a heterogeneous distribution of Orai1 and STIM2 with elevated expression in the invasive rim of the tumor.
|
24472175 |
2014 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype.
|
22125164 |
2012 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Analysis of microarray data from 295 breast cancers showed that the transcriptional breast cancer subtype with the poorest prognosis (basal) was associated with an altered relationship between the ORAI1 regulators STIM1 and STIM2, and that women with breast cancers with STIM1(high)/STIM2(low) tumors had a significantly poorer prognosis.
|
21224390 |
2011 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
This high-resolution analysis allowed us to propose novel candidate target genes such as STIM2 at 4p15, and TNFSF13B or COL4A2 at 13q32-34 that could potentially contribute to the pathogenesis of these tumors and which would require futher investigations.
|
17002787 |
2006 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings were validated in human tissue arrays of 340 breast cancer samples for STIM2.
|
31464639 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2.
|
31287239 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.020 |
Biomarker
|
disease |
BEFREE |
To identify factors that may predispose to TKI WS, we analysed the pharmacovigilance declarations for the 6 months after stopping TKIs in a large cohort of CML (n = 427) that combined the French patients included in the STop IMatinib 2 (STIM2; n = 224) and EURO-SKI (n = 203) trials.
|
31271217 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings were validated in human tissue arrays of 340 breast cancer samples for STIM2.
|
31464639 |
2019 |
|
Huntington Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Unlike the AD setting, in the striatum from Huntington's disease (HD) transgenic mice, an increased STIM2 expression causes elevated synaptic SOCE that was suggested to underlie synaptic loss in medium spiny neurons.
|
29623030 |
2018 |
|
Huntington Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of HAP1A in the human neuroblastoma cell line SK-N-SH (i.e., a cellular model of HD (SK-N-SH HTT138Q)) led to the appearance of a pool of constitutively active SOC channels and an increase in the expression of STIM2 protein.
|
30455632 |
2018 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
STIM2 has also been proposed as a relevant player in pathological conditions related to ageing, Alzheimer's and Huntington's diseases, autoimmune disorders and cancer.
|
28087881 |
2017 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Patients with autosomal recessive mutations in the CRAC channel gene ORAI1, its activator stromal interaction molecule 1 (STIM1), and mice with targeted deletion of Orai1, Stim1, and Stim2 genes reveal important roles for CRAC channels in adaptive and innate immune responses to infection and in autoimmunity.
|
22129055 |
2011 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Analysis of microarray data from 295 breast cancers showed that the transcriptional breast cancer subtype with the poorest prognosis (basal) was associated with an altered relationship between the ORAI1 regulators STIM1 and STIM2, and that women with breast cancers with STIM1(high)/STIM2(low) tumors had a significantly poorer prognosis.
|
21224390 |
2011 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Analysis of microarray data from 295 breast cancers showed that the transcriptional breast cancer subtype with the poorest prognosis (basal) was associated with an altered relationship between the ORAI1 regulators STIM1 and STIM2, and that women with breast cancers with STIM1(high)/STIM2(low) tumors had a significantly poorer prognosis.
|
21224390 |
2011 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Despite defective T cell activation, mice deficient in both Stim1 and Stim2 in T cells (conditional double knockout [cDKO]) developed lymphoproliferative disorders and skin inflammation with a concomitant increase in serum IgG1 and IgE levels.
|
30910863 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, there are no studies on the role of stromal interaction molecule (STIM) and its two subtypes, STIM1 and STIM2, in the epithelial-to-mesenchymal transition (EMT) of podocytes induced by diabetic kidney disease (DKD).
|
30475382 |
2019 |
|
Lymphoproliferative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Despite defective T cell activation, mice deficient in both Stim1 and Stim2 in T cells (conditional double knockout [cDKO]) developed lymphoproliferative disorders and skin inflammation with a concomitant increase in serum IgG1 and IgE levels.
|
30910863 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, STIM2 overexpression promoted metastasis.
|
31464639 |
2019 |